Europe’s CHMP top scientific committee gave a positive opinion for approval to cladribine, with the proposed trade name Mavenclad, for relapsing forms of MS with high disease activity.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...